Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

FDA Grants Frontline Avelumab/Axitinib Breakthrough Designation for RCC

December 21st 2017

The FDA has granted the PD-L1 inhibitor avelumab a breakthrough therapy designation for use in combination with the VEGF inhibitor axitinib in treatment-naïve patients with advanced renal cell carcinoma.

Future of Bladder Cancer Likely to Be Combination Immunotherapy

December 21st 2017

Arjun Balar, MD, discusses novel immunotherapy combinations for the treatment of patients with bladder cancer.

FDA Grants Apalutamide Priority Review for Nonmetastatic CRPC

December 21st 2017

The FDA has granted a priority review to a new drug application for apalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Apolo on Toxicity Challenges With Checkpoint Inhibitors in Bladder Cancer

December 21st 2017

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses challenges with managing toxicities of checkpoint inhibitors for patients with bladder cancer.

Dr. McKay on FDA Approval of Frontline Cabozantinib in RCC

December 20th 2017

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of cabozantinib (Cabometyx) in the frontline setting for patients with renal cell carcinoma (RCC).

FDA Approves Frontline Cabozantinib for Advanced RCC

December 20th 2017

The FDA has approved cabozantinib for previously untreated patients with advanced renal cell carcinoma.

Pembrolizumab Investigated as Adjuvant RCC Therapy

December 18th 2017

Tian Zhang, MD, discusses KEYNOTE-564, as well as the progress that immunotherapy has made in the treatment paradigm of patients with RCC.

Dr. Oh Discusses Choosing Abiraterone in Prostate Cancer

December 14th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.

Dr. McDermott on Single-Agent Nivolumab in RCC

December 14th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses nivolumab (Opdivo) as a single-agent for the treatment of patients with renal cell carcinoma.

A Practice Model Designed to Reward Physician Partners Equally

December 14th 2017

Associated Medical Professionals of New York, a urology and radiation oncology practice, seeks to give its physician partners an equal share of its financial success while rewarding all staff members according to their levels of responsibility and workflow intensity.

FDA Grants Nivolumab/Ipilimumab Priority Review for RCC

December 14th 2017

The FDA has granted a priority review to a sBLA for use of the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced RCC.

Apolo Discusses Managing Immune-Related Toxicities in Bladder Cancer

December 14th 2017

Andrea Apolo, MD, discusses the management of immune-related adverse events in the treatment of bladder cancer.

Active Surveillance Underused in Prostate Cancer Patients Who Want to Preserve Sexual Function

December 13th 2017

In results from the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study, 52.6% said that preserving sexual function was “very important,” but only 43.4% were assigned to active surveillance.

Dr. Plimack on Second-Line Checkpoint Inhibitors in Bladder Cancer

December 12th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the approved checkpoint inhibitors for the second-line treatment of patients with bladder cancer.

Atezolizumab Plus Bevacizumab Meets Primary Endpoint for PFS in Advanced or Metastatic mRCC

December 12th 2017

In top-line results from the phase III IMmotion151 trial, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) was associated with a statistically significant reduction in the risk for death or progression in patients with PD-L1

Dr. McKay Discusses Immunotherapy Trials in RCC

December 12th 2017

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy trials in renal cell carcinoma.

Dr. Zhang Discusses the KEYNOTE-564 Trial in RCC

December 8th 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma.

Immunotherapy Combinations Poised to Shift Standard of Care in RCC

December 7th 2017

Hans Hammers, MD, PhD, discusses the game-changing combination of nivolumab and ipilimumab and highlighted other combinations that have potential in the treatment of patients with renal cell carcinoma.

Dr. Grivas on the Next Steps for Immunotherapy in Bladder Cancer

December 7th 2017

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses next steps for immunotherapy for the treatment of patients with bladder cancer.

Dr. Armstrong on Sipuleucel-T in Prostate Cancer

December 7th 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses sipuleucel-T (Provenge) for patients with prostate cancer.